Clinical Trial Update: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa [Phase 3]

View source ↗

Summary

A Phase 3 study update describes continued access to efanesoctocog alfa for patients who completed a prior trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Efanesoctocog alfa (efanesoctocog alfa)

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Haemophilia A (Moderate or Severe) | Phase 3 | Status: RECRUITING